Aspergillus clavatus – Morphology, Life Cycle, Pathogenesis

• Aspergillus clavatus is a species of fungus in the genus Aspergillus.
• It was first described scientifically in 1834 by the French mycologist John Baptiste Henri Joseph Desmazières.
• The name “Aspergillus” itself was used by Micheli (1729) for moulds with a brush-like spore structure.
• In taxonomy it is placed under family Aspergillaceae, order Eurotiales.
• During the 20th century, A. clavatus was grouped in a section called Clavati (or “clavatus group”) by Thom & Church (1926).
• Later, additional species (such as A. rhizopodus, A. longivesica, A. clavatonanicus) were added in that Section Clavati / Clavati section.
• In 1979 Samson concluded that Aspergillus pallidus is a white variant (synonym) of A. clavatus, based on identical DNA sequence data.
• A sexual stage (teleomorph) was described recently (2018) under the genus Neocarpenteles but under the “one fungus–one name” convention, the A. clavatus name was retained.
• Morphologically, the fungus is characterized by club-shaped (clavate) vesicles, uniseriate phialides over the entire surface, and blue-green uniseriate conidia.
• Conidia size is about 3–4.5 × 2.5–4.5 µm.
• Growth in culture: on Czapek’s agar, it can reach 3.0–3.5 cm in 10 days at 24–26 °C.
• Historically A. clavatus has been studied not only for its morphology but for its production of secondary metabolites / toxins (such as patulin).
• In 1942, Wiesner noted that A. clavatus produced an antibiotic (initially called clavatin, later clavacin), which was linked to patulin.
• In 1943, A. clavatus strains were reported capable of sterilizing liquid media infected with Staphylococcus aureus (i.e. antibacterial effects).
• Geographically, A. clavatus is cosmopolitan. It has been found in soil, dung, decomposing material across tropical, subtropical, Mediterranean and temperate regions.
• It is often seen as a spoilage fungus on cereals, stored grains (especially when moisture is present) and in alkaline environments (it is alkali-tolerant).
• In malting of barley, A. clavatus may grow and sometimes reach undesirable levels if conditions (temperature, humidity) are favorable.
• Pathogenicity: it is not a frequent aggressive pathogen, but is allergenic (causes hypersensitivity pneumonitis, e.g. malt-worker’s lung).
• Some cases of pulmonary infections / aspergillosis have been associated with A. clavatus, especially in immunocompromised persons.
• In animals, neurotoxicosis (in sheep) has been reported.
• Modern genomics: ~80 % of genes are shared with A. fumigatus among identified genes, but only ~30 % of secondary metabolite (SM) genes are conserved.
• A strain ATCC 1007 (= A. clavatus) is held in culture collections and is used for antibiotic / metabolite research.
• The past & present studies of A. clavatus reflect both its role as a mold of interest (toxins, antibiotics) and as a mild opportunistic organism.

Habitat of Aspergillus clavatus

• Aspergillus clavatus is usually found in soil (especially cultivated soils) and animal manure / dung.
• It is also isolated from rotting organic waste / decomposing material (plant debris, compost) in many habitats.
• In stored cereals / grains (rice, corn, millet etc) under humid / moist conditions it is seen as a spoilage mold.
• It has been detected in alkaline substrates because it is alkali-tolerant, allowing growth in high pH soils or decayed material.
• The geographic range is cosmopolitan: tropical, subtropical, Mediterranean, temperate zones are inhabited by it.
• It has been found in low frequencies in soils of India, Bangladesh, Sri Lanka, also in USA, Greece, Egypt, etc.
• It can colonize rhizosphere soils (soil close to roots) of plants like banana, ground-nut, wheat.
• It was recovered even from rock / cave substrates and deep stratigraphic cores (down to ~1200 m in Japan).
• Within indoor or built environments it is less common, but it may appear in moist / wet surfaces, damp walls, or humid storage areas.
• Due to its xerophilic (low-water requirement) tendencies it can occur on relatively dry substrates, especially where others fail.
• It is also isolated from insects (dead adult bees, honeycombs), bird droppings / feathers, showing it can inhabit / survive on biotic surfaces.
• Growth is favored in moderate temperature (~25 °C) but growth has been reported from min ~5 °C to max ~42 °C in culture, so its habitat range is broad in thermal tolerance.
• In agricultural soils it is often associated with crops like barley, potatoes, sugar cane, cotton, legumes.
• It is stimulated by nitrogen / NPK fertilizers (in some reports) in soils / compost, thereby becoming more abundant under enriched nutrient conditions.
• Its presence in a habitat is influenced by moisture, pH, nutrient content, substrate type (organic matter), temperature, and competition from other microbes.
• It may persist in habitats even when conditions become less favorable (e.g. dry periods) because of spore resilience / dormancy.

Morphology of Aspergillus clavatus

• Aspergillus clavatus is composed of septate, hyaline hyphae which are multicellular and branching.
• The conidiophores are long, erect, smooth‐walled stalks (1.5–3.0 mm in many strains) that arise from the vegetative mycelium.
• At the apex of each conidiophore a clavate (club-shaped) vesicle is formed (i.e. swelling) which is thicker toward its apex.
• The phialides (sterigmata) are borne uniseriately (in a single row) over the entire surface of the vesicle.
• The sterigmata are numerous, crowded, and each supports a conidium (i.e. conidial chains).
• The conidia are elliptical (or broadly ellipsoidal), smooth, relatively thick‐walled.
• Conidial dimensions are about 3.0 – 4.5 × 2.5 – 3.5 µm in many isolates.
• In young state, conidial heads are large and clavate, but with maturity they often split into two or more divergent columns of chains.
• Colony (macroscopic) appearance: a velvety to felted texture, often bluish-green in color, with a white periphery in many culture media.
• Growth rate on e.g. Czapek’s agar: reaches ~3.0–3.5 cm in 10 days at ~24-26 °C in many strains.
• The reverse side of the colony (underside) is usually uncolored initially but may turn brown in some strains over time.
• Some isolates produce a sexual structure (cleistothecia / asci / ascospores) under appropriate conditions (after several weeks) in crosses.
• Cleistothecia are often yellowish-brown to dark brown, with a hard outer wall (peridium), diameter ~315-700 µm.
• Ascospores inside the cleistothecia are clear, lenticular, typically ~6.0–7.0 µm in diameter (with ridges).
• The wall composition of conidia / cell walls contains soluble wall carbohydrates such as mannitol and arabitol in many isolates.
• The GC content of DNA (in studied strains) is ~52.5–55 %.
• By TEM / SEM studies it has been shown that first-formed conidium and its phialide may share a continuous wall in early development.
• Some variation is seen among strains: under different media (malt extract agar etc) the abundance, size, and compactness of conidial heads may differ.
• In the taxonomy of section Clavati, A. clavatus and related species share the clavate vesicle trait, but A. clavatus is differentiated by its particular vesicle / conidial features.

Cultural Characteristics of Aspergillus clavatus

• On Czapek’s solution agar (CYA / Czapek’s agar) Aspergillus clavatus is rapidly grown and colonies of ~ 3.0-3.5 cm diameter are produced in 8–10 days at ~24–26 °C.
• Colony form is plane to slightly furrowed, often floccose (woolly / wool-like) with a thin mycelial felt bearing erect conidiophores.
• The color of the colony surface is bluish-grey green (or blue-green) with a white margin / periphery.
• The underside / reverse of the colony (on agar) is usually uncoloured or pale / white to tan, though in some strains it may turn brown over time.
• On Czapek agar, odor is generally weak or absent, but in some strains an unpleasant smell / odor may develop.
• Conidial heads in early growth (on CYA) are relatively large, club-shaped (clavate), maybe ~300–400 µm × 150–200 µm when young.
• As maturity occurs, conidial heads often split into two or more divergent columns / chains of conidia (divergent heads) reaching lengths ~1.00 mm in some strains.
• Conidiophores (on CZA) reach lengths ~1.5-3.0 mm with diameter ~20–30 µm; stipes are smooth-walled, hyaline, colorless initially.
• Vesicles are clavate (club-shaped), enlarged at apex (200–250 µm long × 40–60 µm width in many strains) as the fertile region supporting phialides.
• Phialides (sterigmata) are uniseriate (single row) over the full surface of the vesicle, numerous and crowded.
• Conidia are elliptical / broadly ellipsoidal, smooth, thick-walled. Their size is ~3.0–4.5 × 2.5–3.5 µm in many cases.
• On malt extract agar (MEA / malt agar) the morphology differs: fewer conidial structures are produced, sometimes heads are smaller, conidiophore length / abundance may reduce, and strong odor may be more prominent.
• Colony appearance on malt agar may include more loose, columnar heads, weaker / smaller conidiophores (300–500 µm) in non-typical strains.
• In crosses / sexual culture: cleistothecia are produced after 4–10 weeks (on suitable media, ~25 °C).
• Cleistothecia are yellowish-brown to dark brown, diameter ~315–700 µm, with hard peridium.
• Ascospores (in cleistothecia) are clear, lenticular (with ridges), ~6.0–7.0 µm in diameter.
• Variation is observed among strains / media: size, density, odor, branching, head-splitting patterns differ.
• Growth temperature influences cultural traits: at ~25 °C the described morphology is standard; extremes may reduce sporulation or alter morphology.

Culture media used for the growth of Aspergillus clavatus

• A common medium used for Aspergillus clavatus is Czapek’s solution agar (Czapek agar / CZA) — on this medium A. clavatus is vigorously grown, and colonies of ~3.0–3.5 cm are formed in ~10 days at 24-26 °C.
• Growth on malt extract agar (MEA) is also employed; on MEA fewer conidial structures may be produced, colony morphology may differ (looser heads, weaker sporulation) compared to Czapek’s medium.
• Use of DG18 agar (dichloran-glycerol agar) has been mentioned as a medium used for environmental Aspergillus (for xerophilic / moisture-limiting growth), in which Aspergillus species like A. clavatus might be recovered under lower water activity conditions.
• Sabouraud’s dextrose agar (SDA / Sabouraud’s medium) is sometimes used especially when fungi are recovered from clinical / mixed samples; Aspergillus colonies (including A. clavatus) may grow on it.
• In pH / selective media like CREA (creatinine sucrose agar) the fungus has been observed to influence / alter pH (by releasing acidic substances), and may grow / survive in such media (used in mold diagnostics) — so CREA is used in some fungal / mold media surveys.
• In selective / inhibitory media (i.e. media containing antibiotics or dyes) A. clavatus may be isolated when bacterial growth is suppressed (for example, MEA + chloramphenicol is often used in environmental fungal culture) (this is general for Aspergillus spp.)

Life Cycle of Aspergillus clavatus

• The life cycle of Aspergillus clavatus is dominated by asexual reproduction, though a functional sexual cycle has been discovered.
• Asexual reproduction is accomplished by formation of conidia (asexual spores) on conidiophores; these conidia are dispersed (by air, dust) to new substrates.
• Upon landing on a suitable substrate (nutrient, moisture, temperature favorable), the conidium is germinated; a germ tube is formed and hyphal growth begins (vegetative mycelium).
• The mycelium (hyphae network) spreads by apical extension and branching, and substrate mycelium is formed.
• Under favorable conditions, aerial hyphae differentiate to form conidiophores which develop vesicles, phialides, sterigmata, and conidial chains (i.e. the asexual fruiting).
• In A. clavatus, the conidiophore length is often ~1.5-3.0 mm, vesicle is clavate (club-shaped), phialides uniseriate over entire vesicle surface, conidia ~3.0–4.5 × 2.5–3.5 µm.
• The asexual cycle continues as conidia are produced repeatedly, and the fungus colonizes new niches.
• Sexual reproduction (in A. clavatus) is achieved via the formation of cleistothecia (closed fruiting bodies) under specific cultured conditions (e.g. oatmeal agar, sealed plates, darkness, ~25-28 °C) over several weeks (≈4 weeks).
• Inside cleistothecia, karyogamy (nuclear fusion) + meiosis occur, leading to ascospores which are borne in asci. The ascospores are heat-resistant, hyaline, often with two equatorial ridges.
• After ascospores mature, they are released (or liberated when cleistothecia rupture) into the environment; they then germinate, restarting the cycle.
• Genetic recombination is enabled via the sexual cycle: isolates of MAT1-1 and MAT1-2 mating types have been observed and crossing (outcrossing) was confirmed by molecular markers in ascospore progeny.
• The relative frequency of sexual vs asexual reproduction is skewed: asexual reproduction dominates under most natural conditions, while sexual cycle is induced under special lab or stress conditions.
• A parasexual cycle may be possible (as in other Aspergillus spp), where hyphal fusion / heterokaryosis / mitotic recombination can lead to genetic variation without a full sexual cycle.
• Variation among strains in capacity / ease to undergo sexual cycle is observed; not all isolates will readily form cleistothecia under given conditions.
• The life cycle phases (asexual spore → germination → vegetative growth → conidiation; sexual mating → cleistothecia → ascospores) ensure both propagation and potential for genetic diversity.

Pathogenesis of Aspergillus clavatus

• Exposure is initiated when conidia (asexual spores) of Aspergillus clavatus are inhaled into the respiratory tract (nose, bronchi, alveoli).
• The conidia, being small and airborne, are deposited on airway surfaces (bronchioles, alveoli) where mucosal / alveolar surfaces are contacted.
• Under favorable conditions, the conidia are germinated, and germ tubes emerge, penetrating the epithelial barriers or colonizing the mucosal surface.
• Hyphal growth proceeds by apical extension and branching, forming invasive hyphae that may breach tissue barriers (epithelium, basement membrane).
• Fungal adhesion factors / cell wall components assist in attachment to host cells or matrix; host surfaces are colonized.
• Tissue damage is mediated by enzymes / toxins / metabolites secreted by the fungus (e.g. proteases, ribotoxins, mycotoxins like patulin).
• Inflammatory / immune responses are triggered: neutrophils, macrophages attempt phagocytosis and oxidative killing of the fungal elements.
• In susceptible / immunocompromised hosts, immune defenses are impaired, so hyphal invasion is unchecked, and tissue necrosis / infarction may result.
• Hematogenous dissemination is possible: hyphae or fragments may invade blood vessels (angioinvasion), thereby spreading to distant organs (kidney, brain, skin).
• The fungus is often opportunistic: it is rarely pathogenic in healthy hosts, and strong host immunity usually prevents deep invasion.
• Allergic / hypersensitivity reactions may also occur (non-invasive form): inhaled antigens / spores provoke immune sensitization (extrinsic allergic alveolitis / “malt-worker’s lung”) in exposed persons.
• In animals, ingestion of contaminated food / feed (with spores / toxins) may lead to mycotoxicosis and secondary lesions (e.g. neurotoxic effects).
• In pulmonary infection, alveolar damage, hemorrhage, and granulomatous inflammation may be found; fungal hyphae are seen invading tissues in histological sections.
• Ultimately clearance or control may be achieved by immune mechanisms (phagocytosis, antifungal responses) or the infection may worsen, depending on host status.

Diseases caused by Aspergillus clavatus

• Aspergillus clavatus is known to cause hypersensitivity pneumonitis (extrinsic allergic alveolitis) in humans — especially in malt workers (“malt-worker’s lung”) — by repeated inhalation of spores / antigens.
• In such allergic disease, immune complexes / Type I / III hypersensitivity are involved, and lung parenchyma inflammation with microgranulomas is produced.
• Pulmonary aspergillosis (invasive or chronic) has occasionally been associated with A. clavatus in immunocompromised individuals.
• Mycotoxicosis is a disease risk, because A. clavatus produces patulin (a mycotoxin) and other secondary metabolites which can cause toxicity in animals / humans if ingested / inhaled in high amounts.
• In animals (e.g. sheep), neurotoxicosis has been reported when contaminated feeds (with spores, toxins) are consumed.
• Cases of otomycosis (ear fungal infection) have also been ascribed to A. clavatus in some reports.
• Hyperkeratosis in calves has been linked to exposure to A. clavatus spore derivatives / extracts in experimental settings.
• Pulmonary mycotoxicosis / lung inflammation / tumor induction has been shown in animal experiments where A. clavatus extracts / spore wall components were given to mice (causing lung reaction, inflammatory lesions, occasional tumor increase) in unimmunized mice.

Treatment of Aspergillus clavatus diseases

• Treatment of disease caused by Aspergillus clavatus is not well standardized because the organism is only occasionally pathogenic, and data are limited.
• In pulmonary aspergillosis or invasive aspergillus infections (general Aspergillus therapy), azoles such as voriconazole, isavuconazole or itraconazole are often used as first-line antifungals.
• Amphotericin B (lipid or deoxycholate formulations) is applied as alternative therapy when azoles cannot be used or in severe invasive cases.
• In allergic forms (such as hypersensitivity / pneumonitis, e.g. “malt-worker’s lung”) corticosteroids (systemic immunosuppression) are employed to reduce inflammation.
• Antifungal agents (e.g. itraconazole) may be used adjunctively along with steroids in allergic forms to reduce fungal burden / antigen load.
• For ocular / keratitis / surface infections with Aspergillus species, topical irrigation with voriconazole, amphotericin B, or pimaricin has been described. A. clavatus may respond similarly.
• Supportive care (management of respiratory failure, immunosuppression reversal) is critical in severe disease.
• Duration of therapy is usually prolonged (weeks to months), and treatment must often continue until resolution of lesions and control of underlying risk factors.
• In allergic disease monitoring of IgE levels, imaging and symptoms is done during therapy.
• Preventive measure (minimizing exposure to mold, protective masks) is considered adjunct to therapy to reduce recurrence.
• Because A. clavatus is rare as a pathogen, susceptibility testing and individualized therapy may be required (i.e. adjusting antifungal drug choice/dose).
• In severe refractory cases, combination antifungal therapy or surgical resection (if focal lesion) might be considered (by analogy with invasive aspergillosis guidelines).
• Care must be taken with drug toxicity, drug interactions (especially with azoles) and host immune status in therapy planning.

Prevention and control of Aspergillus clavatus

• Exposure to spores / conidia of Aspergillus clavatus is minimized by removal / reduction of all possible mold sources (walls, damp surfaces, stored grains).
• Moisture control is central: humidity levels are maintained low, leaks and condensation are repaired promptly so that growth is discouraged.
• In indoor or storage environments material (wood, paper, grains) should be kept dry, ventilated, with good air circulation so mold growth is inhibited.
• Use of protective masks / respirators (e.g. N95) is advised for individuals (farm workers, malt workers) in high-spore exposure zones.
• Protective clothing, gloves, boots are recommended so that skin / clothing contamination is limited.
• Surfaces suspected of having mold should be cleaned / decontaminated using appropriate antiseptics / fungicides / biocides and physical removal of biofilm / spores.
• In buildings / hospitals, air filtration, HEPA filters, and positive pressure rooms may be used to prevent spore ingress into sensitive areas (especially immunocompromised patients).
• During construction / renovation in healthcare or residential settings, dust control, wetting down surfaces, sealing off areas are done so mold spread is prevented.
• For high-risk patients (immunocompromised), prophylactic antifungal medication may in some protocols be prescribed to reduce risk of invasive Aspergillus infections.
• Regular monitoring / inspections of buildings, storage facilities, ventilation systems are carried out to detect early mold colonization / humid zones.
• In grain storage, controlling moisture content, aeration, prompt drying after harvest are practiced to prevent A. clavatus proliferation.
• In occupational / industrial settings, worker education (on risks, exposure) and routine environmental surveillance (air sampling, spore counts) are used as control measures.
• Barrier methods (e.g., sealed containers, impermeable packaging) are used for susceptible materials / products to avoid contamination.

FAQ